HDAC9 and myelodysplastic syndrome: 5-Azacytidine (AZA) and 5-aza-2′-deoxycitidine (decitabine) were approved by the FDA in 2004 and 2006 for myelodysplastic syndrome (MDS), while the HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) was approved in 2006 for the treatment of persistent or cutaneous T cell lymphoma [43].